Menu
Search
|

Menu

Close
X

ProQR Therapeutics NV PRQR.OQ (NASDAQ Stock Exchange Global Market)

8.59 USD
-- (--)
As of Jul 18
Previous Close 8.59
Open --
Volume --
3m Avg Volume 49,050
Today’s High --
Today’s Low --
52 Week High 24.00
52 Week Low 6.40
Shares Outstanding (mil) 24.11
Market Capitalization (mil) 112.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, EUR)
FY19
0
FY18
6
FY17
1
FY16
2
EPS (EUR)
FY19
-0.364
FY18
-1.075
FY17
-1.729
FY16
-1.675
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
79.24
7.92
Price to Book (MRQ)
vs sector
2.60
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
16.54
14.56
LT Debt to Equity (MRQ)
vs sector
16.54
10.21
Return on Investment (TTM)
vs sector
-68.51
14.49
Return on Equity (TTM)
vs sector
-75.74
15.79

EXECUTIVE LEADERSHIP

Daniel De Boer
Founding Chief Executive Officer, Since 2012
Salary: --
Bonus: --
Gerard Platenburg
Co-Founder, Chief Innovation Officer, Since
Salary: --
Bonus: --
Smital Shah
Chief Business and Financial Officer, Since 2018
Salary: --
Bonus: --
Lisa Hayes
Vice President - Investor Relations and Corporate Communications, Since 2018
Salary: --
Bonus: --
Tiffany Burt
Vice President, Head - Commercial, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Zernikedreef 9
LEIDEN     2333 CK

Phone: +31854.894932

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

SPONSORED STORIES